Gastrointestinal Stromal Tumor: Clinicopathological Features, Management, and Comparison of Three Risk Stratification Schemes
Hashem, W., El-Nahas, T., Fawzy, M., Mashhour, S., Zedan, M., Mashhour, K. (2021). Gastrointestinal Stromal Tumor: Clinicopathological Features, Management, and Comparison of Three Risk Stratification Schemes. EKB Journal Management System, 17(2), 73-79. doi: 10.21608/resoncol.2021.40562.1113
Wedad B. Hashem; Tamer El-Nahas; Marine Fawzy; Shady Mashhour; Mohamed Zedan; Karim Mashhour. "Gastrointestinal Stromal Tumor: Clinicopathological Features, Management, and Comparison of Three Risk Stratification Schemes". EKB Journal Management System, 17, 2, 2021, 73-79. doi: 10.21608/resoncol.2021.40562.1113
Hashem, W., El-Nahas, T., Fawzy, M., Mashhour, S., Zedan, M., Mashhour, K. (2021). 'Gastrointestinal Stromal Tumor: Clinicopathological Features, Management, and Comparison of Three Risk Stratification Schemes', EKB Journal Management System, 17(2), pp. 73-79. doi: 10.21608/resoncol.2021.40562.1113
Hashem, W., El-Nahas, T., Fawzy, M., Mashhour, S., Zedan, M., Mashhour, K. Gastrointestinal Stromal Tumor: Clinicopathological Features, Management, and Comparison of Three Risk Stratification Schemes. EKB Journal Management System, 2021; 17(2): 73-79. doi: 10.21608/resoncol.2021.40562.1113

Gastrointestinal Stromal Tumor: Clinicopathological Features, Management, and Comparison of Three Risk Stratification Schemes

Research in Oncology
Article 5, Volume 17, Issue 2, December 2021, Page 73-79  XML PDF (321.15 K)
Document Type: Original Article
DOI: 10.21608/resoncol.2021.40562.1113
View on SCiNiTO View on SCiNiTO
Authors
Wedad B. Hashem1; Tamer El-Nahas1; Marine Fawzy1; Shady Mashhour2; Mohamed Zedan3; Karim Mashhour email orcid 1
1Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
2Radiology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
3Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt
Abstract
Background: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. To optimize its management, different risk stratification schemes had been developed for GIST.
Aim:To describe the clinicopathological profile and management of GIST and to evaluate three different GIST risk stratification schemes.
Methods: Retrospective review of patients treated in a single Egyptian center during an 11-year period. High-risk GIST was identified using three different risk stratification schemes; the Armed Forces Institute of Pathology (AFIP) scheme, the National Institute of Health (NIH) consensus scheme and the American Joint Committee on Cancer (AJCC) TNM staging system.
Results: The disease extent at the presentation of 34 patients was localized in 19 (56%), locally advanced in 4 (12%) and metastatic in 11 (32%). Twenty-one (62%) underwent surgery and achieved complete remission. Their median overall survival was not reached. The median disease-free survival (DFS) was 58.2 months (95%CI: 28.8 – 58.2) and the 3-year rate was 66%. Non-gastric GIST, larger tumors (>10cm) and high mitotic index (>5 / 50 HPF) was associated with shorter DFS (p = 0.146, 0.047 and 0.06, respectively). The AFIP, NIH consensus and AJCC TNM risk stratification methods identified high-risk groups that had a significantly shorter median DFS than lower-risk groups (p = 0.022, 0.009 and 0.22, respectively).
Conclusion: All the studied three risk stratification schemes categorized a high-risk group with significantly poorer outcome. According to the information available, any of these schemes may be used in identifying high-risk GIST.
Keywords
Gastrointestinal stromal tumor; Risk stratification; Management; Prognosis
Statistics
Article View: 392
PDF Download: 571